Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) EPS (Weighted Average and Diluted) (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed EPS (Weighted Average and Diluted) for 4 consecutive years, with -$0.48 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 47.25% to -$0.48 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.47 through Dec 2025, up 28.64% year-over-year, with the annual reading at -$1.46 for FY2025, 29.13% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.48 at Centessa Pharmaceuticals, down from -$0.41 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was -$0.2 in Q1 2025, with the low at -$0.91 in Q4 2024.
  • Average EPS (Weighted Average and Diluted) over 4 years is -$0.46, with a median of -$0.4 recorded in 2025.
  • The sharpest move saw EPS (Weighted Average and Diluted) surged 62.32% in 2023, then plummeted 145.95% in 2024.
  • Over 4 years, EPS (Weighted Average and Diluted) stood at -$0.45 in 2022, then grew by 17.78% to -$0.37 in 2023, then tumbled by 145.95% to -$0.91 in 2024, then soared by 47.25% to -$0.48 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.48, -$0.41, and -$0.38 for Q4 2025, Q3 2025, and Q2 2025 respectively.